adjuvant endocrine therapy for breast cancer: optimal durations and regimens
Published 1 year ago • 418 plays • Length 6:09Download video MP4
Download video MP3
Similar videos
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
0:35
duration of endocrine therapy in early breast cancer
-
8:30
hr breast cancer: endocrine therapy, surgery and radiotherapy
-
6:23
stratifying patients with breast cancer by a 7-gene assay for endocrine therapy
-
1:30
exploring endocrine therapy innovations for high-risk hormone receptor-positive breast cancer
-
1:26
dr. burstein on adjuvant endocrine therapy for er breast cancer
-
3:12
combination treatments for premenopausal breast cancer: endocrine therapy and ovarian suppression
-
8:18
endocrine therapy in premenopausal women with hr breast cancer
-
0:45
is there a potential benefit of intermediate duration of adjuvant endocrine therapy?
-
48:22
adjuvant endocrine therapy for high-risk breast cancer
-
10:02
breast cancer: extended adjuvant endocrine therapy
-
3:11
st. gallen consensus 2021: neoadjuvant and adjuvant therapy for her2 breast cancer
-
1:38
unanswered questions in the use of adjuvant therapy in early breast cancer
-
1:56
exploring extended adjuvant endocrine therapy for hr breast cancer
-
1:50
challenges with patient selection for extended adjuvant endocrine therapy in breast cancer
-
2:33
challenges with neoadjuvant endocrine therapy in breast cancer
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
22:48
adjuvant therapy of breast cancer